nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluocinonide—SMO—Hedgehog Signaling Pathway—PTCH1—muscle cancer	0.118	0.172	CbGpPWpGaD
Fluocinonide—SMO—Signaling events mediated by the Hedgehog family—PTCH1—muscle cancer	0.0879	0.129	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—TP63—muscle cancer	0.0725	0.106	CbGpPWpGaD
Fluocinonide—SMO—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—muscle cancer	0.0543	0.0795	CbGpPWpGaD
Fluocinonide—SMO—embryo—muscle cancer	0.0502	0.16	CbGeAlD
Fluocinonide—SMO—Hedgehog signaling events mediated by Gli proteins—PTCH1—muscle cancer	0.0488	0.0714	CbGpPWpGaD
Fluocinonide—SMO—cardiac atrium—muscle cancer	0.034	0.108	CbGeAlD
Fluocinonide—SMO—Class B/2 (Secretin family receptors)—PTCH1—muscle cancer	0.0303	0.0444	CbGpPWpGaD
Fluocinonide—SMO—tendon—muscle cancer	0.0297	0.0945	CbGeAlD
Fluocinonide—SMO—Hedgehog 'off' state—PTCH1—muscle cancer	0.0276	0.0403	CbGpPWpGaD
Fluocinonide—SMO—vagina—muscle cancer	0.0275	0.0877	CbGeAlD
Fluocinonide—SMO—head—muscle cancer	0.0254	0.081	CbGeAlD
Fluocinonide—SMO—GPCRs, Other—CNR1—muscle cancer	0.0247	0.0361	CbGpPWpGaD
Fluocinonide—SMO—Signaling by Hedgehog—PTCH1—muscle cancer	0.0246	0.036	CbGpPWpGaD
Fluocinonide—SMO—testis—muscle cancer	0.0246	0.0782	CbGeAlD
Fluocinonide—SERPINA6—renal system—muscle cancer	0.0209	0.0667	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.019	0.0278	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.0186	0.0273	CbGpPWpGaD
Fluocinonide—SERPINA6—bone marrow—muscle cancer	0.0158	0.0504	CbGeAlD
Fluocinonide—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—muscle cancer	0.0146	0.0214	CbGpPWpGaD
Fluocinonide—SERPINA6—head—muscle cancer	0.014	0.0446	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.0139	0.0203	CbGpPWpGaD
Fluocinonide—NR3C1—embryo—muscle cancer	0.0121	0.0386	CbGeAlD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.0103	0.015	CbGpPWpGaD
Fluocinonide—NR3C1—smooth muscle tissue—muscle cancer	0.00952	0.0303	CbGeAlD
Fluocinonide—NR3C1—renal system—muscle cancer	0.00917	0.0292	CbGeAlD
Fluocinonide—SMO—GPCR ligand binding—PTCH1—muscle cancer	0.00829	0.0121	CbGpPWpGaD
Fluocinonide—NR3C1—cardiac atrium—muscle cancer	0.00821	0.0261	CbGeAlD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00745	0.0109	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.00723	0.0106	CbGpPWpGaD
Fluocinonide—NR3C1—tendon—muscle cancer	0.00716	0.0228	CbGeAlD
Fluocinonide—SMO—GPCR ligand binding—CNR1—muscle cancer	0.007	0.0102	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.00698	0.0102	CbGpPWpGaD
Fluocinonide—NR3C1—bone marrow—muscle cancer	0.00693	0.0221	CbGeAlD
Fluocinonide—NR3C1—vagina—muscle cancer	0.00664	0.0211	CbGeAlD
Fluocinonide—SMO—Signaling Pathways—KIDINS220—muscle cancer	0.00639	0.00935	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.00616	0.00902	CbGpPWpGaD
Fluocinonide—NR3C1—head—muscle cancer	0.00613	0.0195	CbGeAlD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.00594	0.00869	CbGpPWpGaD
Fluocinonide—NR3C1—testis—muscle cancer	0.00592	0.0189	CbGeAlD
Fluocinonide—NR3C1—Adipogenesis—HMGA1—muscle cancer	0.00533	0.0078	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.00515	0.00754	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.00468	0.00685	CbGpPWpGaD
Fluocinonide—NR3C1—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.00434	0.00635	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—PTCH1—muscle cancer	0.00425	0.00623	CbGpPWpGaD
Fluocinonide—SMO—Signaling by GPCR—CNR1—muscle cancer	0.00359	0.00526	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—CDKN2A—muscle cancer	0.00358	0.00524	CbGpPWpGaD
Fluocinonide—SMO—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.00353	0.00517	CbGpPWpGaD
Fluocinonide—NR3C1—Adipogenesis—FOXO1—muscle cancer	0.00353	0.00516	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.00306	0.00448	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—PTCH1—muscle cancer	0.00251	0.00368	CbGpPWpGaD
Fluocinonide—NR3C1—Generic Transcription Pathway—MED12—muscle cancer	0.00235	0.00344	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FOXO4—muscle cancer	0.00216	0.00316	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—CNR1—muscle cancer	0.00212	0.00311	CbGpPWpGaD
Fluocinonide—NR3C1—AP-1 transcription factor network—TP53—muscle cancer	0.00199	0.00292	CbGpPWpGaD
Fluocinonide—NR3C1—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.00176	0.00257	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—IGF2—muscle cancer	0.00173	0.00254	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—FOXO1—muscle cancer	0.0016	0.00234	CbGpPWpGaD
Fluocinonide—NR3C1—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.00139	0.00203	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—KIT—muscle cancer	0.00122	0.00178	CbGpPWpGaD
Fluocinonide—NR3C1—Gene Expression—MED12—muscle cancer	0.00113	0.00165	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—MDM2—muscle cancer	0.000958	0.0014	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—VEGFA—muscle cancer	0.000727	0.00106	CbGpPWpGaD
Fluocinonide—SMO—Signaling Pathways—TP53—muscle cancer	0.00055	0.000804	CbGpPWpGaD
Fluocinonide—Telangiectasia—Methotrexate—muscle cancer	0.000217	0.078	CcSEcCtD
Fluocinonide—Eruption—Dactinomycin—muscle cancer	0.000192	0.0689	CcSEcCtD
Fluocinonide—Folliculitis—Dactinomycin—muscle cancer	0.000188	0.0674	CcSEcCtD
Fluocinonide—Secondary infection—Doxorubicin—muscle cancer	0.000151	0.0541	CcSEcCtD
Fluocinonide—Leukoderma—Methotrexate—muscle cancer	0.00012	0.0432	CcSEcCtD
Fluocinonide—Leukoderma—Doxorubicin—muscle cancer	0.000104	0.0374	CcSEcCtD
Fluocinonide—Eruption—Methotrexate—muscle cancer	8.32e-05	0.0299	CcSEcCtD
Fluocinonide—Skin exfoliation—Etoposide—muscle cancer	8.16e-05	0.0293	CcSEcCtD
Fluocinonide—Folliculitis—Methotrexate—muscle cancer	8.15e-05	0.0292	CcSEcCtD
Fluocinonide—Eruption—Doxorubicin—muscle cancer	7.21e-05	0.0259	CcSEcCtD
Fluocinonide—Folliculitis—Doxorubicin—muscle cancer	7.05e-05	0.0253	CcSEcCtD
Fluocinonide—Swelling—Etoposide—muscle cancer	7.03e-05	0.0252	CcSEcCtD
Fluocinonide—Glycosuria—Doxorubicin—muscle cancer	5.47e-05	0.0196	CcSEcCtD
Fluocinonide—Erythema—Dactinomycin—muscle cancer	5.16e-05	0.0185	CcSEcCtD
Fluocinonide—Skin exfoliation—Methotrexate—muscle cancer	4.89e-05	0.0175	CcSEcCtD
Fluocinonide—Dermatitis contact—Doxorubicin—muscle cancer	4.38e-05	0.0157	CcSEcCtD
Fluocinonide—Skin exfoliation—Doxorubicin—muscle cancer	4.23e-05	0.0152	CcSEcCtD
Fluocinonide—Infection—Dactinomycin—muscle cancer	4.19e-05	0.015	CcSEcCtD
Fluocinonide—Immune system disorder—Etoposide—muscle cancer	3.88e-05	0.0139	CcSEcCtD
Fluocinonide—Infection—Vincristine—muscle cancer	3.74e-05	0.0134	CcSEcCtD
Fluocinonide—Nervous system disorder—Vincristine—muscle cancer	3.69e-05	0.0132	CcSEcCtD
Fluocinonide—Pain—Dactinomycin—muscle cancer	3.6e-05	0.0129	CcSEcCtD
Fluocinonide—Pain—Vincristine—muscle cancer	3.22e-05	0.0116	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	3.16e-05	0.0113	CcSEcCtD
Fluocinonide—Hypersensitivity—Dactinomycin—muscle cancer	3.1e-05	0.0111	CcSEcCtD
Fluocinonide—Infection—Etoposide—muscle cancer	3.03e-05	0.0109	CcSEcCtD
Fluocinonide—Skin disorder—Etoposide—muscle cancer	2.96e-05	0.0106	CcSEcCtD
Fluocinonide—Dry skin—Doxorubicin—muscle cancer	2.95e-05	0.0106	CcSEcCtD
Fluocinonide—Nasopharyngitis—Doxorubicin—muscle cancer	2.88e-05	0.0103	CcSEcCtD
Fluocinonide—Hypersensitivity—Vincristine—muscle cancer	2.77e-05	0.00995	CcSEcCtD
Fluocinonide—Rash—Dactinomycin—muscle cancer	2.66e-05	0.00953	CcSEcCtD
Fluocinonide—Pain—Etoposide—muscle cancer	2.61e-05	0.00936	CcSEcCtD
Fluocinonide—Hyperglycaemia—Doxorubicin—muscle cancer	2.51e-05	0.009	CcSEcCtD
Fluocinonide—Dizziness—Vincristine—muscle cancer	2.49e-05	0.00893	CcSEcCtD
Fluocinonide—Rash—Vincristine—muscle cancer	2.37e-05	0.00852	CcSEcCtD
Fluocinonide—Dermatitis—Vincristine—muscle cancer	2.37e-05	0.00851	CcSEcCtD
Fluocinonide—Headache—Vincristine—muscle cancer	2.36e-05	0.00846	CcSEcCtD
Fluocinonide—Immune system disorder—Methotrexate—muscle cancer	2.32e-05	0.00833	CcSEcCtD
Fluocinonide—Hypersensitivity—Etoposide—muscle cancer	2.25e-05	0.00806	CcSEcCtD
Fluocinonide—Erythema—Methotrexate—muscle cancer	2.24e-05	0.00803	CcSEcCtD
Fluocinonide—Pruritus—Etoposide—muscle cancer	2.16e-05	0.00774	CcSEcCtD
Fluocinonide—Dizziness—Etoposide—muscle cancer	2.02e-05	0.00724	CcSEcCtD
Fluocinonide—Immune system disorder—Doxorubicin—muscle cancer	2.01e-05	0.00722	CcSEcCtD
Fluocinonide—Erythema—Doxorubicin—muscle cancer	1.94e-05	0.00696	CcSEcCtD
Fluocinonide—Rash—Etoposide—muscle cancer	1.92e-05	0.0069	CcSEcCtD
Fluocinonide—Dermatitis—Etoposide—muscle cancer	1.92e-05	0.00689	CcSEcCtD
Fluocinonide—Headache—Etoposide—muscle cancer	1.91e-05	0.00686	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	1.89e-05	0.00679	CcSEcCtD
Fluocinonide—Infection—Methotrexate—muscle cancer	1.81e-05	0.00651	CcSEcCtD
Fluocinonide—Nervous system disorder—Methotrexate—muscle cancer	1.79e-05	0.00643	CcSEcCtD
Fluocinonide—Skin disorder—Methotrexate—muscle cancer	1.77e-05	0.00637	CcSEcCtD
Fluocinonide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	1.64e-05	0.00588	CcSEcCtD
Fluocinonide—Infection—Doxorubicin—muscle cancer	1.57e-05	0.00564	CcSEcCtD
Fluocinonide—Pain—Methotrexate—muscle cancer	1.56e-05	0.00561	CcSEcCtD
Fluocinonide—Nervous system disorder—Doxorubicin—muscle cancer	1.55e-05	0.00557	CcSEcCtD
Fluocinonide—Skin disorder—Doxorubicin—muscle cancer	1.54e-05	0.00551	CcSEcCtD
Fluocinonide—Pain—Doxorubicin—muscle cancer	1.35e-05	0.00485	CcSEcCtD
Fluocinonide—Hypersensitivity—Methotrexate—muscle cancer	1.35e-05	0.00483	CcSEcCtD
Fluocinonide—Pruritus—Methotrexate—muscle cancer	1.29e-05	0.00464	CcSEcCtD
Fluocinonide—Dizziness—Methotrexate—muscle cancer	1.21e-05	0.00434	CcSEcCtD
Fluocinonide—Hypersensitivity—Doxorubicin—muscle cancer	1.17e-05	0.00418	CcSEcCtD
Fluocinonide—Rash—Methotrexate—muscle cancer	1.15e-05	0.00413	CcSEcCtD
Fluocinonide—Dermatitis—Methotrexate—muscle cancer	1.15e-05	0.00413	CcSEcCtD
Fluocinonide—Headache—Methotrexate—muscle cancer	1.14e-05	0.00411	CcSEcCtD
Fluocinonide—Pruritus—Doxorubicin—muscle cancer	1.12e-05	0.00402	CcSEcCtD
Fluocinonide—Dizziness—Doxorubicin—muscle cancer	1.05e-05	0.00375	CcSEcCtD
Fluocinonide—Rash—Doxorubicin—muscle cancer	9.97e-06	0.00358	CcSEcCtD
Fluocinonide—Dermatitis—Doxorubicin—muscle cancer	9.97e-06	0.00358	CcSEcCtD
Fluocinonide—Headache—Doxorubicin—muscle cancer	9.91e-06	0.00356	CcSEcCtD
